Insulet Corporation (PODD): a likely value trap?

Avoid — guidance cut over slowing Type 2 patient demand plus an active fraud lawsuit over product defects signal real deterioration, not overreaction.

⚠ TRAP Fundamentals80/100

Fell 22% in 6 trading day(s) — now $133.26

Why PODD dropped

PODD cut its full-year 2026 revenue growth outlook after management admitted it was slow to spot Type 2 diabetes patient retention and usage problems, and this hit alongside an already-running securities fraud class action over undisclosed Omnipod manufacturing/tubing defects that triggered two prior stock drops in March and May 2026.

Fwd P/E 16.8Op margin 16.2%Rev growth 23.5%Debt/equity 66.7%Analyst upside 76.8%

How this scored 80/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 12.3%

✅ Generates cash Free cash flow unknown

✅ Not drowning in debt Debt/equity 66.7% (limit 200%)

✅ Can pay its bills Current ratio 2.5 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 19/25

Operating margin 16.2% 6/9

Net profit margin 12.3% 5/8

Return on equity 26.0% 8/8

Growth Is it getting bigger, or dying? 25/25

Revenue growth 23.5% 9/9

Earnings growth 328.6% 8/8

Expected profit change 48.4% 8/8

Value Is it cheap right now? 19/25

Forward P/E 16.8 7/10

PEG ratio 1.5 5/8

Analyst target upside 76.8% 7/7

Balance sheet Will it survive? 17/25

Debt / equity 66.7% 7/10

Current ratio 2.5 8/8

Free cash flow unknown 2/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for PODD — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-06. Research only — not financial advice.